The changing profile of ankylosing spondylitis in the biologic era

[1]  P. Machado.  Faculty Opinions recommendation of 2019 update of the american college of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  M. Ward,et al.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis , 2019, Arthritis care & research.

[3]  M. Brown,et al.  HLA class I and II alleles in susceptibility to ankylosing spondylitis , 2018, Annals of the rheumatic diseases.

[4]  Manouchehr Hessabi,et al.  Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort , 2018, Contemporary clinical trials communications.

[5]  M. Brown,et al.  Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort , 2017, The Journal of Rheumatology.

[6]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[7]  Søren Brunak,et al.  Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci , 2016, Nature Genetics.

[8]  John D Reveille,et al.  Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1 , 2015, Nature Communications.

[9]  L. Bradbury,et al.  ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients , 2015, Annals of the rheumatic diseases.

[10]  M. Dougados,et al.  Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. , 2015, Rheumatology.

[11]  L. Bradbury,et al.  Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and Differences in Associations Observed With Ankylosing Spondylitis , 2015, Arthritis & rheumatology.

[12]  D. Gladman,et al.  Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis , 2014, Annals of the rheumatic diseases.

[13]  Tae-Hwan Kim,et al.  HLA-B27 homozygosity has no influence on radiographic damage in ankylosing spondylitis: Observation Study of Korean spondyloArthropathy Registry (OSKAR) data. , 2013, Joint, bone, spine : revue du rhumatisme.

[14]  J. Reveille,et al.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.

[15]  Désirée van der Heijde,et al.  Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. , 2013, Rheumatology.

[16]  Peter Donnelly,et al.  Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci , 2013, Nature Genetics.

[17]  E. Märker-Hermann,et al.  Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC) , 2013, Annals of the rheumatic diseases.

[18]  J. Braun,et al.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis , 2013, Annals of the rheumatic diseases.

[19]  M. Dougados,et al.  The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. , 2011, Joint, bone, spine : revue du rhumatisme.

[20]  J. Reveille,et al.  The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. , 2011, Rheumatology.

[21]  Paul Weston,et al.  Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility , 2011, Nature Genetics.

[22]  J. Reveille,et al.  Psychological correlates of self-reported disease activity in ankylosing spondylitis. , 2010, The Journal of rheumatology.

[23]  Michael M. Ward,et al.  Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci , 2010, Nature Genetics.

[24]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[25]  J. Reveille,et al.  Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. , 2008, Arthritis and rheumatism.

[26]  M. A. van 't Hof,et al.  Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system , 2004, Annals of the rheumatic diseases.

[27]  A. Calin,et al.  The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. , 1998, Arthritis and rheumatism.

[28]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[29]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[30]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[31]  L. Radloff.  The CES-D Scale , 1977 .

[32]  D. Wallis,et al.  Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. , 2015, Rheumatology.

[33]  J. Reveille,et al.  The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis , 2014 .

[34]  M. Reijnierse,et al.  Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. , 2013, Rheumatology.

[35]  Laura Diekman,et al.  Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis , 2009, Arthritis research & therapy.

[36]  P. Donnelly,et al.  Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. , 2007, Nature genetics.